Immupharma PLC - Clinical Development Collaboration with Incanthera
("ImmuPharma" or the "Company")
UPDATE ON NUCANT CANCER PROGRAMME
Clinical Development Collaboration with Incanthera
As announced on
It is now envisaged that the 'Definitive Licence Agreement' will be finalised in the first quarter of 2019 and as such, a further update on this collaboration will be announced in due course.
Commenting, Dimitri Dimitriou, ImmuPharma's Chief Executive Officer, said:
"We are working diligently with Incanthera's management team to finalise the last remaining parts to the 'Definitive Licence Agreement' and look forward to updating the market and shareholders in Q1 2019."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact:
This information is provided by RNS, the news service of the
Quick facts: ImmuPharma PLC
Market Cap: £17.2 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE